EGFR and neoplasm: The significant difference in tumor status between the CT + TT and CC genotypes in EGFR wild-type patients was also observed in an evaluation of all patients, in which 43.9% with the CT + TT genotype had more advanced (T3/T4) tumors compared with 27.8% with the CC genotype (p = 0.016).